X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
https://www.otsuka.co.jp/en/company/newsreleases/2023/20231110_1.html
https://www.pharmiweb.com/press-release/2023-05-03/otsuka-announces-nice-recommendation-of-lupkynis-voclosporin-with-mycophenolate-mofetil-for-treating-active-lupus-nephritis
https://www.ema.europa.eu/en/documents/overview/lupkynis-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/major-shifts-in-management-of-patients-with-lupus-nephritis-spurred-by-availability-of-aurinia-pharmaceuticals-lupkynis-and-gsks-benlysta-according-to-spherix-global-insights-301726407.html
https://www.pharmacompass.com/pdf/news/otsukas-lupkynis-voclosporin-receives-approval-in-europe-59592.pdf
https://www.pharmiweb.com/press-release/2022-09-20/otsuka-announces-ec-approval-of-lupkynis-voclosporin-as-first-oral-treatment-for-active-lupus-nephritis
https://ir.auriniapharma.com/press-releases/detail/263/aurinia-announces-european-commission-approval-of
https://www.businesswire.com/news/home/20220919005617/en/Aurinia-Announces-European-Commission-Approval-of-LUPKYNIS%C2%AE-voclosporin-for-the-Treatment-of-Lupus-Nephritis
https://www.biospace.com/article/gsk-and-aurinia-will-they-won-t-they-/?s=79
https://ir.auriniapharma.com/press-releases/detail/239/aurinia-announces-updated-interim-results-from-the-aurora-2
https://finance.yahoo.com/news/aurinia-pharmaceuticals-present-five-abstracts-201000428.html
https://www.businesswire.com/news/home/20210408005099/en/Aurinia-Presents-Data-Demonstrating-LUPKYNIS%E2%84%A2-voclosporin-Efficacy-Across-Lupus-Nephritis-Biopsy-Classes-at-National-Kidney-Foundation-2021-Spring-Clinical-Meetings
https://ir.auriniapharma.com/press-releases/detail/207/aurinia-and-lonza-announce-exclusive-agreement-for#:~:text=(SIX%3A%20LONN)%20(%22,API%20facility%20in%20Visp%2C%20Switzerland.
https://www.clinicaltrialsarena.com/news/aurinia-initiates-voclosporin-trial-in-ktrs-with-covid-19/
https://ir.auriniapharma.com/press-releases/detail/199/aurinia-presents-voclosporin-efficacy-and-pharmacokinetic
https://icer-review.org/announcements/icer-to-assess-treatments-for-lupus-nephritis/
https://ir.auriniapharma.com/press-releases/detail/184/aurinia-presents-aurora-pivotal-trial-subgroup-analysis-at
https://ir.auriniapharma.com/press-releases/detail/181/aurinia-completes-submission-of-new-drug-application-to-the
https://www.fiercebiotech.com/biotech/aurinia-soars-as-phase-3-lupus-study-hits-primary-endpoint
https://markets.businessinsider.com/news/stocks/aurinia-announces-positive-aurora-phase-3-trial-results-demonstrating-voclosporin-superiority-over-standard-of-care-in-lupus-nephritis-1028738632
https://www.clinicaltrialsarena.com/news/aurinia-voclosporin-dry-eye-disease/
https://www.businesswire.com/news/home/20191016005281/en/Aurinia-Reports-Patient-Study-Visit-Aurora-Phase/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
http://www.outsourcing-pharma.com/Clinical-Development/Worldwide-Clinical-Trials-supporting-Ph-III-trial-of-Lupus-drug
http://www.in-pharmatechnologist.com/Ingredients/Lonza-contracted-to-make-API-for-Aurinia-s-lupus-nephritis-candidate
http://seekingalpha.com/article/4021530-aurinia-pharmaceuticals-great-upside-potential-entering-phase-3-trial
https://scrip.pharmamedtechbi.com/SC097607/Aurinia-Has-FDA-OK-For-Phase-III-Voclosporin-Trialing-In-Lupus-Nephritis
http://www.prnewswire.com/news-releases/lupus-research-alliance-welcomes-voclosporin-trial-results-300316997.html
http://www.biospace.com/News/aurinias-voclosporin-meets-primary-endpoint-in/429385/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews
http://www.businesswire.com/news/home/20170616005320/en/Voclosporin-Remission-Data-Phase-IIb-AURA-LV-Study/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
Market Place
Share 
